Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RiMO-401 with radiation in advanced tumors
NCT06182579Phase 1Terminated
- Sponsor
- Coordination Pharmaceuticals, Inc.
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rimo-401 in solid tumor (advanced stage), sponsored by Coordination Pharmaceuticals, Inc. Primary endpoint: Determination of Recommended Dose at 45 days. Started Feb 2024; status: terminated.
02
Drugs
rimo-401
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06182579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182579.